340 related articles for article (PubMed ID: 23187933)
1. The role of treatment modality on the utility of predictive tissue biomarkers in clinical prostate cancer: a systematic review.
Kachroo N; Gnanapragasam VJ
J Cancer Res Clin Oncol; 2013 Jan; 139(1):1-24. PubMed ID: 23187933
[TBL] [Abstract][Full Text] [Related]
2. Biological effect of neoadjuvant androgen-deprivation therapy assessed on specimens from radical prostatectomy: a systematic review.
Antonelli A; Palumbo C; Veccia A; Grisanti S; Triggiani L; Zamboni S; Furlan M; Simeone C; Magrini S; Berruti A
Minerva Urol Nefrol; 2018 Aug; 70(4):370-379. PubMed ID: 29392925
[TBL] [Abstract][Full Text] [Related]
3. Androgen deprivation modulates gene expression profile along prostate cancer progression.
Volante M; Tota D; Giorcelli J; Bollito E; Napoli F; Vatrano S; Buttigliero C; Molinaro L; Gontero P; Porpiglia F; Tucci M; Papotti M; Berruti A; Rapa I
Hum Pathol; 2016 Oct; 56():81-8. PubMed ID: 27342909
[TBL] [Abstract][Full Text] [Related]
4. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial.
Denham JW; Steigler A; Lamb DS; Joseph D; Turner S; Matthews J; Atkinson C; North J; Christie D; Spry NA; Tai KH; Wynne C; D'Este C
Lancet Oncol; 2011 May; 12(5):451-9. PubMed ID: 21440505
[TBL] [Abstract][Full Text] [Related]
5. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing surgical treatment for prostate cancer.
Gomella LG; Zeltser I; Valicenti RK
Urology; 2003 Dec; 62 Suppl 1():46-54. PubMed ID: 14747041
[TBL] [Abstract][Full Text] [Related]
6. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
Haines IE; Gabor Miklos GL
J Natl Cancer Inst; 2013 Oct; 105(20):1534-9. PubMed ID: 24092918
[TBL] [Abstract][Full Text] [Related]
7. Differential Risk of Castration Resistance After Initial Radical Prostatectomy or Radiotherapy for Prostate Cancer.
Obata H; Shiota M; Akitake N; Takeuchi A; Kashiwagi E; Dejima T; Kiyoshima K; Inokuchi J; Tatsugami K; Eto M
Anticancer Res; 2017 Oct; 37(10):5631-5637. PubMed ID: 28982880
[TBL] [Abstract][Full Text] [Related]
8. Prospective Validation of Diagnostic Tumor Biomarkers in Men Treated With Radiotherapy for Prostate Cancer.
Pollack A; Kwon D; Walker G; Khor LY; Horwitz EM; Buyyounouski MK; Stoyanova R
J Natl Cancer Inst; 2017 Feb; 109(2):1-8. PubMed ID: 28376214
[TBL] [Abstract][Full Text] [Related]
9. Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.
Akakura K; Tsuji H; Suzuki H; Ichikawa T; Ishikawa H; Okada T; Kamada T; Harada M; Tsujii H; Shimazaki J
Jpn J Clin Oncol; 2014 Apr; 44(4):360-5. PubMed ID: 24585931
[TBL] [Abstract][Full Text] [Related]
10. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.
Pearse M; Fraser-Browne C; Davis ID; Duchesne GM; Fisher R; Frydenberg M; Haworth A; Jose C; Joseph DJ; Lim TS; Matthews J; Millar J; Sidhom M; Spry NA; Tang CI; Turner S; Williams SG; Wiltshire K; Woo HH; Kneebone A
BJU Int; 2014 Mar; 113 Suppl 2():7-12. PubMed ID: 24894850
[TBL] [Abstract][Full Text] [Related]
11. Correlation between proliferation, apoptosis, and angiogenesis in prostate carcinoma and their relation to androgen ablation.
Matsushima H; Goto T; Hosaka Y; Kitamura T; Kawabe K
Cancer; 1999 Apr; 85(8):1822-7. PubMed ID: 10223578
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
[TBL] [Abstract][Full Text] [Related]
13. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer.
Siddiqui SA; Boorjian SA; Blute ML; Rangel LJ; Bergstralh EJ; Karnes RJ; Frank I
BJU Int; 2011 Feb; 107(3):383-8. PubMed ID: 21265985
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant and adjuvant hormonal and chemotherapy for prostate cancer.
Lam ET; Glodé LM
Hematol Oncol Clin North Am; 2013 Dec; 27(6):1189-204, viii. PubMed ID: 24188258
[TBL] [Abstract][Full Text] [Related]
15. Targeted androgen pathway suppression in localized prostate cancer: a pilot study.
Mostaghel EA; Nelson PS; Lange P; Lin DW; Taplin ME; Balk S; Ellis W; Kantoff P; Marck B; Tamae D; Matsumoto AM; True LD; Vessella R; Penning T; Hunter Merrill R; Gulati R; Montgomery B
J Clin Oncol; 2014 Jan; 32(3):229-37. PubMed ID: 24323034
[TBL] [Abstract][Full Text] [Related]
16. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases.
Heidenreich A; Fossati N; Pfister D; Suardi N; Montorsi F; Shariat S; Grubmüller B; Gandaglia G; Briganti A; Karnes RJ
Eur Urol Oncol; 2018 May; 1(1):46-53. PubMed ID: 31100228
[TBL] [Abstract][Full Text] [Related]
17. Radiation and hormonal therapy for locally advanced and clinically localized prostate cancer.
D'Amico AV
Urology; 2002 Sep; 60(3 Suppl 1):32-7; discussion 37-8. PubMed ID: 12231043
[TBL] [Abstract][Full Text] [Related]
18. Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer.
Meyer F; Bairati I; Bédard C; Lacombe L; Têtu B; Fradet Y
Urology; 2001 Aug; 58(2 Suppl 1):71-7. PubMed ID: 11502453
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant Approaches Prior To Radical Prostatectomy.
Ryan ST; Patel DN; Parsons JK; McKay RR
Cancer J; 2020; 26(1):2-12. PubMed ID: 31977379
[TBL] [Abstract][Full Text] [Related]
20. [Is maximal androgenic blockade necessary in the treatment of prostatic cancer?].
Matveev BP; Bukharkin BV
Urologiia; 2003; (6):6-10. PubMed ID: 14708235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
